Clinical Trial Update: Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial to evaluate donanemab for amyloid lowering in Alzheimer's disease associated with Down syndrome is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Down Syndrome

Drugs mentioned

• Donanemab (donanemab)

Snippet

Sponsor: Michael Rafii, MD, PhD | Conditions: Down Syndrome (DS), Down Syndrome (Trisomy 21) | Phase 4 | Status: NOT_YET_RECRUITING